Cover Image
市場調查報告書

Orion Oyj的產品平台分析

Orion Oyj - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251701
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
Orion Oyj的產品平台分析 Orion Oyj - Product Pipeline Review - 2016
出版日期: 2016年03月22日 內容資訊: 英文 58 Pages
簡介

Orion Oyj是總公司在芬蘭的製藥企業,進行著人類及動物用的製藥產品和API、診斷測試藥的開發、製造、銷售。核心的治療對象領域為中樞神經系統疾病、腫瘤重症加護、肺部疾病,以醫生、藥局、醫院、健康中心、醫院、研究所等的醫療系服務供應商及專家為主要客戶。

本報告提供Orion Oyj 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Orion Oyj 基本資料

  • Orion Oyj 概要
  • 主要資訊
  • 企業資料

Orion Oyj :R&D概要

  • 主要的治療範圍

Orion Oyj :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Orion Oyj :開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Orion Oyj :藥物簡介

  • (budesonide + formoterol fumarate)
  • (fluticasone propionate + salmeterol)
  • levosimendan
  • ODM-201
  • dexmedetomidine hydrochloride
  • ODM-103
  • ODM-104
  • ODM-203
  • ORM-10103
  • Small Molecules to Inhibit BET Bromodomain for Oncology
  • Small Molecules for Pain

Orion Oyj :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Orion Oyj :最近的開發平台資訊

Orion Oyj :開發休止的計劃

Orion Oyj :開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • deramciclane
    • nitecapone
    • ODM-102
    • ORM-10921
    • SEL-103
    • SEL-103194

Orion Oyj :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07992CDB

Summary

Global Markets Direct's, 'Orion Oyj - Product Pipeline Review - 2016', provides an overview of the Orion Oyj's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Orion Oyj, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Orion Oyj
  • The report provides overview of Orion Oyj including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Orion Oyj's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Orion Oyj's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Orion Oyj's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Orion Oyj
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Orion Oyj's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Orion Oyj Snapshot
    • Orion Oyj Overview
    • Key Information
    • Key Facts
  • Orion Oyj - Research and Development Overview
    • Key Therapeutic Areas
  • Orion Oyj - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Orion Oyj - Pipeline Products Glance
    • Orion Oyj - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Orion Oyj - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Orion Oyj - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Orion Oyj - Drug Profiles
    • (budesonide + formoterol fumarate)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (fluticasone propionate + salmeterol xinafoate)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levosimendan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ODM-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dexmedetomidine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ODM-109
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ODM-204
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ODM-104
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ODM-108
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ODM-203
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Agonize GABA-B Receptor for Central Nervous System Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ORM-10103
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ORM-3819
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit BET Bromodomain for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Orion Oyj - Pipeline Analysis
    • Orion Oyj - Pipeline Products by Target
    • Orion Oyj - Pipeline Products by Route of Administration
    • Orion Oyj - Pipeline Products by Molecule Type
    • Orion Oyj - Pipeline Products by Mechanism of Action
  • Orion Oyj - Recent Pipeline Updates
  • Orion Oyj - Dormant Projects
  • Orion Oyj - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • deramciclane
      • nitecapone
      • ODM-102
      • ODM-106
      • ORM-10921
  • Orion Oyj - Company Statement
  • Orion Oyj - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Orion Oyj, Key Information
  • Orion Oyj, Key Facts
  • Orion Oyj - Pipeline by Indication, 2016
  • Orion Oyj - Pipeline by Stage of Development, 2016
  • Orion Oyj - Monotherapy Products in Pipeline, 2016
  • Orion Oyj - Combination Treatment Modalities in Pipeline, 2016
  • Orion Oyj - Out-Licensed Products in Pipeline, 2016
  • Orion Oyj - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Orion Oyj - Pre-Registration, 2016
  • Orion Oyj - Phase III, 2016
  • Orion Oyj - Phase II, 2016
  • Orion Oyj - Phase I, 2016
  • Orion Oyj - Preclinical, 2016
  • Orion Oyj - Discovery, 2016
  • Orion Oyj - Pipeline by Target, 2016
  • Orion Oyj - Pipeline by Route of Administration, 2016
  • Orion Oyj - Pipeline by Molecule Type, 2016
  • Orion Oyj - Pipeline Products by Mechanism of Action, 2016
  • Orion Oyj - Recent Pipeline Updates, 2016
  • Orion Oyj - Dormant Developmental Projects,2016
  • Orion Oyj - Discontinued Pipeline Products, 2016
  • Orion Oyj, Subsidiaries

List of Figures

  • Orion Oyj - Pipeline by Top 10 Indication, 2016
  • Orion Oyj - Pipeline by Stage of Development, 2016
  • Orion Oyj - Monotherapy Products in Pipeline, 2016
  • Orion Oyj - Combination Treatment Modalities in Pipeline, 2016
  • Orion Oyj - Out-Licensed Products in Pipeline, 2016
  • Orion Oyj - Pipeline by Top 10 Target, 2016
  • Orion Oyj - Pipeline by Route of Administration, 2016
  • Orion Oyj - Pipeline by Molecule Type, 2016
  • Orion Oyj - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top